{"url_path":"/sec/pvct/8-k/2026-06-22/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/315545/0001493152-26-029512-index.html","accession_number":"0001493152-26-029512","cik":"0000315545","ticker":"PVCT","issuer_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/315545/0001493152-26-029512-index.html","primary_entity_key":"0000315545","primary_entity_name":"PROVECTUS BIOPHARMACEUTICALS, INC."},"word_count":466,"has_tables":true,"body_markdown":"**Item\n5.07. Submission of Matters to a Vote of Security Holders.**\n\n \n\nProvectus\nBiopharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) on June\n18, 2026.\n\n \n\nAt\nthe Annual Meeting, the Company’s stockholders voted on five proposals. A brief description and tabulation of votes for each proposal\nare set forth below.\n\n \n\n**Proposal\n1**. The Company’s stockholders elected the following directors for a term of one-year, consistent with the recommendation of\nthe Company’s board of directors (the “Board”). There were 131,619,889 broker non-votes with respect to the proposal.\n\n \n\nName of Candidate \nNumber of Votes \n\n  \nFor  \n\nWithhold Authority\n \n\nWebster Bailey \n 191,823,174  \n 16,387,830 \n\nJohn Lacey, III, M.D. \n 191,947,635  \n 16,263,369 \n\nEd Pershing, CPA \n 197,553,672  \n 10,657,332 \n\nDominic Rodrigues \n 192,036,957  \n 16,174,047 \n\n \n\n**Proposal\n2**. The Company’s stockholders approved the advisory vote on the compensation of the Company’s named executive officers,\nconsistent with the Board’s recommendation. There were 131,619,889 broker non-votes with respect to the proposal.\n\n \n\n  \n\nNumber of Votes\n \n\nFor \n 190,162,705 \n\nAgainst \n 16,667,960 \n\nAbstention \n 1,380,339 \n\n \n\n**Proposal\n3**. The Company’s stockholders ratified the selection of CBIZ CPAs P.C. as the Company’s independent registered public\naccounting firm for 2026, consistent with the Board’s recommendation. There were no broker non-votes with respect to the proposal.\n\n \n\n  \n\nNumber of Votes\n \n\nFor \n 329,742,597 \n\nAgainst \n 7,6914,122 \n\nAbstention \n 2,474,174 \n\n \n\n**Proposal\n4**. The Company’s stockholders authorized the Board to amend the Company’s Certificate of Incorporation, as amended by\nthe Certificate of Designation of Series D Convertible Preferred Stock and Certificate of Designation of Series D-1 Convertible Preferred\nStock (the “Certificates of Designation”), to effect a reverse stock split of the Company’s common stock, Series D\nConvertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio of between 1-for-10 and 1-for-50, where the ratio\nwould be determined by the Board at its discretion, and to make corresponding amendments to the Certificates of Designation to provide\nfor the proportional adjustment of certain terms upon a reverse stock split, consistent with the Board’s recommendation. There\nwere no broker non-votes with respect to the proposal.\n\n \n\n  \n\nNumber of Votes\n \n\nFor \n 315,344,309 \n\nAgainst \n 23,622,833 \n\nAbstention \n 863,751 \n\n \n\n**Proposal\n5**. The Company’s stockholders authorized the Board, given the Company’s stockholders’ approval of Proposal 4, to\namend the Company’s Certificate of Incorporation, as amended by the Certificates of Designation, to decrease the number of authorized\nshares of the Company’s common stock and preferred stock by the same reverse stock split ratio determined by the Board, consistent\nwith the Board’s recommendation. There were no broker non-votes with respect to the proposal.\n\n \n\n  \nNumber of Votes \n\nFor \n 311,771,119 \n\nAgainst \n 22,227,876 \n\nAbstention \n 5,831,898 \n\n \n\n \n\n \n\n** **\n\n**SIGNATURE**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\nDate:\nJune 22, 2026\n\n \n\n \n**PROVECTUS\nBIOPHARMACEUTICALS, INC.**\n\n \n \n \n\n \nBy:\n*/s/\nDominic Rodrigues*\n\n \n \nDominic\nRodrigues\n\n \n \nPresident\n(Principal Executive Officer)"}